Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
F-star Therapeutics downgraded to Market Perform from Outperform at SVB Leerink » 16:02
06/23/22
06/23
16:02
06/23/22
16:02
FSTX

F-star Therapeutics

$6.31 /

+2.31 (+57.75%)

SVB Leerink analyst Daina…

SVB Leerink analyst Daina Graybosch downgraded F-star Therapeutics to Market Perform from Outperform after the company announced an agreement to be acquired by invoX for $7.12 per share.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$6.31 /

+2.31 (+57.75%)

FSTX F-star Therapeutics
$6.31 /

+2.31 (+57.75%)

06/23/22 Laidlaw
F-star Therapeutics downgraded to Hold from Buy at Laidlaw
06/23/22 Ladenburg
F-star Therapeutics downgraded to Neutral from Buy at Ladenburg
06/23/22 William Blair
F-star Therapeutics downgraded to Market Perform from Outperform at William Blair
11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
FSTX F-star Therapeutics
$6.31 /

+2.31 (+57.75%)

Downgrade
F-star Therapeutics downgraded to Hold from Buy at Laidlaw » 13:45
06/23/22
06/23
13:45
06/23/22
13:45
FSTX

F-star Therapeutics

$6.15 /

+2.15 (+53.75%)

Laidlaw analyst Yale Jen…

Laidlaw analyst Yale Jen downgraded F-star Therapeutics to Hold from Buy after the company announced a deal to be acquired by U.K.-based invoX Pharma, a wholly owned subsidiary of China-based Sino Biopharmaceutical. Though the share price has not hit the $7 level since last November, Jen still feels the deal at $7.12 per share undervalues F-star given its "rich pipeline" including four lead assets, the analyst tells investors.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$6.15 /

+2.15 (+53.75%)

FSTX F-star Therapeutics
$6.15 /

+2.15 (+53.75%)

06/23/22 Ladenburg
F-star Therapeutics downgraded to Neutral from Buy at Ladenburg
06/23/22 William Blair
F-star Therapeutics downgraded to Market Perform from Outperform at William Blair
11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
FSTX F-star Therapeutics
$6.15 /

+2.15 (+53.75%)

Downgrade
F-star Therapeutics downgraded to Neutral from Buy at Ladenburg » 13:26
06/23/22
06/23
13:26
06/23/22
13:26
FSTX

F-star Therapeutics

$6.22 /

+2.22 (+55.50%)

Ladenburg analyst Ahu…

Ladenburg analyst Ahu Demir downgraded F-star Therapeutics to Neutral from Buy after the company announced an agreement to be acquired by invoX for $7.12 per share.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$6.22 /

+2.22 (+55.50%)

FSTX F-star Therapeutics
$6.22 /

+2.22 (+55.50%)

06/23/22 William Blair
F-star Therapeutics downgraded to Market Perform from Outperform at William Blair
11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
07/08/21 SVB Leerink
F-star Therapeutics initiated with an Outperform at SVB Leerink
FSTX F-star Therapeutics
$6.22 /

+2.22 (+55.50%)

Downgrade
F-star Therapeutics downgraded to Market Perform from Outperform at William Blair » 10:22
06/23/22
06/23
10:22
06/23/22
10:22
FSTX

F-star Therapeutics

$6.26 /

+2.26 (+56.50%)

William Blair analyst…

William Blair analyst Matt Phipps downgraded F-star Therapeutics to Market Perform from Outperform after the company announced an agreement whereby invoX will acquire all of the issued and outstanding shares of F-star common stock for $7.12 per share.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$6.26 /

+2.26 (+56.50%)

FSTX F-star Therapeutics
$6.26 /

+2.26 (+56.50%)

11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
07/08/21 SVB Leerink
F-star Therapeutics initiated with an Outperform at SVB Leerink
FSTX F-star Therapeutics
$6.26 /

+2.26 (+56.50%)

Hot Stocks
F star Therapeutics trading resumes  08:00
06/23/22
06/23
08:00
06/23/22
08:00
FSTX

F-star Therapeutics

$4.00 /

+0.375 (+10.34%)

 
ShowHide Related Items >><<
FSTX F-star Therapeutics
$4.00 /

+0.375 (+10.34%)

FSTX F-star Therapeutics
$4.00 /

+0.375 (+10.34%)

11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
07/08/21 SVB Leerink
F-star Therapeutics initiated with an Outperform at SVB Leerink
FSTX F-star Therapeutics
$4.00 /

+0.375 (+10.34%)

Hot Stocks
invoX Pharma to acquire F-star Therapeutics for $7.12 per share » 07:33
06/23/22
06/23
07:33
06/23/22
07:33
SBMFF

Sino Biopharm

/

+

, FSTX

F-star Therapeutics

$4.00 /

+0.375 (+10.34%)

invoX Pharma, a wholly…

invoX Pharma, a wholly owned subsidiary of Sino Biopharmaceutical (SBMFF) and F-star Therapeutics, Inc. (FSTX) announced that the companies have entered into a definitive agreement whereby invoX will acquire all of the issued and outstanding shares of F-star common stock for $7.12 per share. The proposed acquisition values F-star at approximately $161 million. The transaction has been unanimously approved by the invoX and F-star Boards of Directors and is expected to close in the second half of 2022. F-star's proprietary platform technology pioneers the use of tetravalent bispecific antibodies that enable the simultaneous targeting of two different antigens and a unique set of pharmacology to deliver focused, potent and safe immune activation in the tumor microenvironment. Four programs are progressing in clinic, three based on F-star's tetravalent platform and one next generation STING agonist, with multiple further undisclosed programs in development. These programs represent potentially first- and best-in-class drug candidates for many areas of unmet medical need, including patients with cancer and other serious diseases who have few other options available. Leveraging its modular antibody technology, F-star has forged collaborations with major international biopharma companies across a wide range of therapeutic areas including oncology, immunology and neurology. invoX, established in 2021 in the United Kingdom, is Sino Biopharm's international expansion platform, focusing on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics. F-star will form a key element of invoX's strategy to accelerate Sino Biopharm's development of innovative medicines to transform the lives of patients worldwide, complementing its existing R&D platforms and pipeline. Under the terms of the merger agreement, invoX, a wholly owned subsidiary of Sino Biopharm, will commence a tender offer within the next 10 business days to acquire all of the issued and outstanding shares of F-star common stock for a price of $7.12 per share in cash upon the completion of the offer. The transaction is expected to complete in the second half of 2022, subject to certain customary closing conditions, including the tender by F-star stockholders of greater than 50 percent of the issued and outstanding shares of F-star common stock and required regulatory approvals, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions. Following the closing of the tender offer, invoX will acquire any shares of F-star that are not tendered in the tender through a second-step merger under Delaware law at the tender offer price.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$4.00 /

+0.375 (+10.34%)

SBMFF Sino Biopharm
/

+

FSTX F-star Therapeutics
$4.00 /

+0.375 (+10.34%)

11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
07/08/21 SVB Leerink
F-star Therapeutics initiated with an Outperform at SVB Leerink
FSTX F-star Therapeutics
$4.00 /

+0.375 (+10.34%)

Hot Stocks
F star Therapeutics trading halted, news pending  07:31
06/23/22
06/23
07:31
06/23/22
07:31
FSTX

F-star Therapeutics

$4.00 /

+0.375 (+10.34%)

 
ShowHide Related Items >><<
FSTX F-star Therapeutics
$4.00 /

+0.375 (+10.34%)

FSTX F-star Therapeutics
$4.00 /

+0.375 (+10.34%)

11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
07/08/21 SVB Leerink
F-star Therapeutics initiated with an Outperform at SVB Leerink
FSTX F-star Therapeutics
$4.00 /

+0.375 (+10.34%)

Over a month ago
Hot Stocks
F-star Therapeutics announces upcoming milestones » 08:04
05/10/22
05/10
08:04
05/10/22
08:04
FSTX

F-star Therapeutics

$2.24 /

-0.205 (-8.38%)

Anticipated 2022 Program…

Anticipated 2022 Program Milestones: A clinical efficacy readout of FS118 in PD-1 acquired resistance head and neck cancer patients who have failed checkpoint therapies. Clinical update on FS222 Phase 1 trial. Clinical update on the Phase 1 trial of FS120 and initiation of the combination with Merck's pembrolizumab. Clinical update of the dose-escalation study of SB 11285.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$2.24 /

-0.205 (-8.38%)

FSTX F-star Therapeutics
$2.24 /

-0.205 (-8.38%)

11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
07/08/21 SVB Leerink
F-star Therapeutics initiated with an Outperform at SVB Leerink
06/09/21 B. Riley
B. Riley starts F-star Therapeutics at Buy, sees 307% potential upside
FSTX F-star Therapeutics
$2.24 /

-0.205 (-8.38%)

Earnings
F-star Therapeutics reports Q1 EPS (57c), consensus (67c) » 08:04
05/10/22
05/10
08:04
05/10/22
08:04
FSTX

F-star Therapeutics

$2.24 /

-0.205 (-8.38%)

Reports Q1 revenue…

Reports Q1 revenue $2.551M, consensus $1.3M. "This year is one of the most important years in F-star's history, with data readouts expected across all four of our clinical programs, expansion of our partnering activities, and continued development of our organization," said Eliot Forster, CEO of F-star Therapeutics, Inc. "During the quarter, we increased the number of clinical sites for FS118 and FS120 by expanding beyond the US into the EU. We have also further advanced our understanding of the differentiated mechanism of FS118 in modulating LAG-3 cell surface expression. F-star continues to execute and create value for shareholders by advancing our programs and enabling our partners to develop next-generation bispecific therapeutics by leveraging the power of our discovery platform."

ShowHide Related Items >><<
FSTX F-star Therapeutics
$2.24 /

-0.205 (-8.38%)

FSTX F-star Therapeutics
$2.24 /

-0.205 (-8.38%)

11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
07/08/21 SVB Leerink
F-star Therapeutics initiated with an Outperform at SVB Leerink
06/09/21 B. Riley
B. Riley starts F-star Therapeutics at Buy, sees 307% potential upside
FSTX F-star Therapeutics
$2.24 /

-0.205 (-8.38%)

Conference/Events
F-star Therapeutics management to meet with William Blair » 05:55
04/26/22
04/26
05:55
04/26/22
05:55
FSTX

F-star Therapeutics

$3.07 /

-0.2 (-6.12%)

Meetings to be held in…

Meetings to be held in Chicago April 25-26 hosted by William Blair.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$3.07 /

-0.2 (-6.12%)

FSTX F-star Therapeutics
$3.07 /

-0.2 (-6.12%)

11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
07/08/21 SVB Leerink
F-star Therapeutics initiated with an Outperform at SVB Leerink
06/09/21 B. Riley
B. Riley starts F-star Therapeutics at Buy, sees 307% potential upside
FSTX F-star Therapeutics
$3.07 /

-0.2 (-6.12%)

  • 09
    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.